Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
X Bioscience PCLBKK:XBIO +16.67% PS Ratio is 1.21 as of Sep. 02, 2026, which is 30% below its 10-year median of 1.74. The stock has 6 warning signs investors should review. Among 359 Restaurants companies, X Bioscience PCL ranks worse than 64.62% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, X Bioscience PCL's share price is ฿0.07.
X Bioscience PCL's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was ฿0.06. Hence, X Bioscience PCL's PS Ratio for today is 1.21.
The historical rank and industry rank for X Bioscience PCL's PS Ratio or its related term are showing as below:
BKK:XBIO'
s PS Ratio Range Over the Past 10 Years
Min: 0.22 Med: 1.74 Max: 16.52
Current: 1.2
During the past 13 years, X Bioscience PCL's highest PS Ratio was 16.52. The lowest was 0.22. And the median was 1.74.
BKK:XBIO's PS Ratio is ranked worse than 64.62% of 359
companies
in the Restaurants industry
Industry Median: 0.86
vs BKK:XBIO: 1.20
X Bioscience PCL revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of X Bioscience PCL was -86.20% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -36.50% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -30.80% per year.
During the past 10 years, the average Revenue per Share Growth Rate was -51.00% per year.
During the past 13 years, X Bioscience PCL's highest 3-Year average Revenue per Share Growth Rate was 5.30% per year. The lowest was -76.40% per year. And the median was -16.10% per year.
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
X Bioscience PCL PS Ratio Related Terms
X Bioscience PCL PS Ratio Historical Data
* Premium members only.
The historical data trend for X Bioscience PCL's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Restaurants subindustry, X Bioscience PCL's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
X Bioscience PCL PS Ratio vs Restaurants Industry
For the Restaurants industry and Consumer Cyclical sector, X Bioscience PCL's PS Ratio distribution charts can be found below:
* The bar in red indicates where X Bioscience PCL's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
X Bioscience PCL's Share Price of today is ฿0.07. X Bioscience PCL's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ฿0.06.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
X Bioscience PCL (BKK:XBIO) has a PS Ratio of 1.21 as of Sep. 02, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on X Bioscience PCL and its competitors. This is 30% below median its historical median of 1.74. Over the past decade, X Bioscience PCL's PS Ratio has ranged from 0.22 to 16.52. According to the industry distribution chart, X Bioscience PCL ranks #232 out of 359 companies in the Restaurants industry, placing it in the top 64.6%.
Is X Bioscience PCL's PS Ratio too high?
X Bioscience PCL's current PS Ratio of 1.21 is 30% below median its 10-year median of 1.74. Over the past 10 years, this metric has ranged from a low of 0.22 to a high of 16.52. The Restaurants industry median PS Ratio is 0.86. X Bioscience PCL's value of 1.21 is 40.7% above this industry median. Based on the distribution chart, X Bioscience PCL ranks #232 out of 359 companies in the Restaurants industry, which is below the industry midpoint.
How does X Bioscience PCL's PS Ratio compare to MCD and SBUX?
According to the Restaurants industry distribution chart, X Bioscience PCL ranks #232 out of 359 companies for PS Ratio. This places X Bioscience PCL in the lower half of its industry. The industry median PS Ratio is 0.86. X Bioscience PCL's value of 1.21 is 40.7% above this benchmark. Historically, X Bioscience PCL's own PS Ratio has ranged from 0.22 to 16.52 over the past decade. While the company's 10-year median is 1.74 vs. the industry median of 0.86, X Bioscience PCL has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Restaurants company?
The median PS Ratio among Restaurants companies is 0.86, based on 359 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. X Bioscience PCL's current PS Ratio of 1.21 is 40.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on X Bioscience PCL and its competitors. For the Restaurants industry, the median PS Ratio is 0.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. X Bioscience PCL's current PS Ratio is 1.21, which is 30% below median its own 10-year median of 1.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is X Bioscience PCL stock overvalued right now?
Based on GuruFocus' analysis, X Bioscience PCL (BKK:XBIO) is currently considered Modestly Undervalued. The stock's GF Value™ is ฿0.09, compared to a current price of ฿0.07 — trading 22.2% below its estimated fair value. The current PS Ratio is 1.21, which is 30% below median its 10-year median of 1.74 and 40.7% above the Restaurants industry median of 0.86. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For X Bioscience PCL (BKK:XBIO), the current PS Ratio is 1.21 as of Sep. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
X Bioscience PCL, along with its subsidiaries, is mainly engaged in selling food and beverages by operating restaurants and bakery shops under the Le Boeuf, Kagonoya, Bake Cheese Tart, Croquant Chou ZakuZaku, and RAPL trademarks. Additionally, the Group is involved in the production and distribution of biological products. It operates in two business segments: the food and beverage sales segment, which generates maximum revenue, and the production and distribution of biological products segment. Geographically, the Group operates only in Thailand.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:XBIO has been successfully added to your 
